Ask ten clinical operations leaders about AI and you will hear ten different pilot stories. Some saved weeks on document preparation. Others spent months on a tool that never left the test environment. The difference usually has little to do with the technology itself.
AI is being applied across the trial lifecycle, though maturity varies by task. Common uses include:
Feasibility and site selection: analyzing historical performance and patient availability to shortlist sites
In each case, the strongest results come when AI supports a person who remains responsible for the decision.
The risks are practical, not theoretical. Poor-quality input data produces poor-quality output. Tools that cannot explain how they reached a result are hard to defend in an inspection. Sensitive participant data may be exposed if vendors handle it carelessly. And teams can place too much trust in a confident-sounding answer.
How transparent is the vendor? You should be able to learn how the tool works, how it changes over time and how your data is protected.
If a vendor cannot answer these clearly, the tool is not ready for regulated work.
Regulators expect sponsors to maintain control of quality and data integrity regardless of the tools used. A simple governance model helps: a named owner for each tool, a risk assessment before use, clear documentation of intended purpose, and periodic review once the tool is live. This need not be heavy. It does need to exist before the pilot grows into a standard process.
Pilots rarely fail because the algorithm is weak. They stall because:
The problem was not well defined at the start
Data security or compliance questions arrive late and halt progress
Teams that avoid these traps tend to start small, pick a task with a clear measure of success and involve the people who will use the tool daily.
Turning AI into trusted, practical tools while safeguarding quality, data security and compliance is the first key topic of the Evolution Summit, held 19 to 20 January 2027 at the Four Seasons Hotel Westlake Village.
The program draws on leaders working at the intersection of operations and technology. Terri Roberson, AVP, Clinical Operations and Tech Solutions at Eli Lilly, Jeff Cohen, Associate Director, Digital Health, Immunology at Johnson & Johnson, Ramya Palacholla, Director, Digital Science at Evinova (AstraZeneca), and John Rootenberg, Principal Director, Digital Safety and Decision Support at Genentech, are among the speakers. Their roles reflect the range of questions executives face, from workflow design to safety decision support.
The Summit combines executive case studies with peer benchmarking, so delegates can compare what has worked, what has stalled and what they would do differently. For senior leaders deciding where to invest next, that candid exchange is hard to find elsewhere.
Enquire Today - https://www.marcusevans.com/summit/evolution/jan27